Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
The Future of HNSCC: Aligning Teams, Transforming Care
Ravindra Uppaluri, MD, PhD
Nancy Lee, MD, FASTRO
Target Locked in gMG: Why T2T Matters
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
When to Begin FcRn: Initiation Criteria, Key Evidence
The 2-Point Signal: Apply ≥2-Point Rule
The IgG Clock: Redose Using IgG Kinetics
Shared Goals, Shared Gains: Align With Patient Preferences
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
April 13, 2026 Pittsburgh, Pennsylvania
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026 Orlando, Florida
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Turning Flares Into Function: Flag Uncontrolled Disease
April 13, 2026
Pittsburgh, Pennsylvania
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
David Staskin, MD
Matt T. Rosenberg, MD
Kennedy Koebbe, MSN, RN
IgAN SOC: Strengths and Limits
Dana Rizk, MD
Suzuki Yusuke, MD, PhD
Minimal By Design: Define MSE Endpoints
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
Escalate With Intention: Stepwise, Target-Anchored Moves
Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
Richard Lafayette, MD, FACP
Hong Zhang
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
Mechanism-Based Targeting: Why APRIL Matters in IgAN
September 30, 2026
11:45 AM - 12:45 PM ET
12:00 PM - 01:00 PM ET
APRIL Uncovered: An Upstream Driver in IgAN
Emerging Evidence: IgAN Disease-Modifying Agents
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
Emerging Therapies in IgAN: Who Could Benefit the Most?
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.